SHILPAMED.NSSHILPAMED.NSNSE
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank41
3Y CAGR-66.9%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-66.9%/yr
vs -3.5%/yr prior
Acceleration
-63.4pp
Decelerating
Percentile
P41
Within normal range
vs 3Y Ago
0x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.98% |
| Q3 2025 | 25.10% |
| Q2 2025 | 30.76% |
| Q1 2025 | -7.56% |
| Q4 2024 | -10.12% |
| Q3 2024 | 24.16% |
| Q2 2024 | 7.04% |
| Q1 2024 | 9.91% |
| Q4 2023 | 21.94% |
| Q3 2023 | 53.06% |
| Q2 2023 | 56.83% |
| Q1 2023 | 31.42% |
| Q4 2022 | 192.47% |
| Q3 2022 | -500.39% |
| Q2 2022 | -103.88% |
| Q1 2022 | 95.35% |
| Q4 2021 | -28.08% |
| Q3 2021 | 138.48% |
| Q2 2021 | 440.30% |
| Q1 2021 | -63.60% |
| Q4 2020 | -87.06% |
| Q3 2020 | 4.80% |
| Q2 2020 | 55.39% |
| Q1 2020 | -45.24% |
| Q4 2019 | 9.48% |
| Q3 2019 | 216.05% |
| Q2 2019 | -32.45% |
| Q1 2019 | 79.98% |
| Q4 2018 | -45.78% |
| Q3 2018 | -38.09% |
| Q2 2018 | 21.21% |
| Q1 2018 | 104.42% |
| Q4 2017 | -62.87% |
| Q3 2017 | 56.62% |
| Q2 2017 | -39.31% |
| Q1 2017 | 75.81% |
| Q4 2016 | -30.27% |
| Q3 2016 | -23.41% |
| Q2 2016 | 22.70% |
| Q1 2016 | 44.96% |